Authors
Latest:
CMS Signals Looming Sunshine Act Audits: How to PrepareNew guidance suggests that CMS may be ramping up Sunshine Act auditing activities, potentially resulting in monetary liability for noncompliant reporting entities.
Latest:
Manage Risk Effectively to Improve the Value of Your AllianceIn this article, Eli Lilly & Co. examines risk management in the context of partnerships with other companies.
Latest:
The Diversity Mindset: Benefits of Tapping External SourcesSeeking opportunities to be more inclusive can help pharma companies gain a deeper understanding of key opinion leader and patient perspectives and build diversity into the entire product journey.
Latest:
The 8 Market Access Performance Metrics You Should Be TrackingThis guide offers an in-depth analysis of the essential KPIs that market access teams should track to measure success particularly across speed of access, breadth of access, and price performance. It includes real-life use cases and practical steps on how to get started.
Latest:
Why Medical Engagement With Key Opinion Leaders Drives Treatment Adoption: Q&A with Dan Rizzo, global head of Veeva business consultingWith treatments becoming more complex, the life sciences industry needs more professionals with specialized knowledge.
Latest:
IDNs — So What?The U.S. healthcare system has undergone significant changes, particularly in the pharmaceutical industry, due to factors like telemedicine, integrated delivery networks, and value-based care. This has challenged traditional sales models and increased the need for more strategic engagement with clinical executives.
Latest:
Scale Down Before Scaling Up: Digital Innovation in a Highly Regulated IndustryThe highly-regulated pharmaceutical industry poses serious challenges that can derail digital health programs. But, there are solutions.
Latest:
Combining Regulatory Pathways to Optimize Development EfficiencyMultiple regulatory pathways exist during the drug development process.
Latest:
MSL Teams Need to Digitize, or Face Being Left BehindMedical science liaisons (MSL) in the pharma industry were already at their limit pre-COVID. The challenge for MSLs is to identify the most efficient way to upskill their teams and add digital competencies without overloading them.
Latest:
Sustainability and Progress Continue to Make Headlines in 2024Recognition of the business case for ESG in pharma is soaring.
Latest:
Measuring Omnichannel Efforts in Medical AffairsA five-step pilot approach to effective measurement of medical affairs omnichannel efforts.
Latest:
Final ThoughtsThe future of CAR T-cell therapies will continue to improve as they expand to other patients in need.
Latest:
The State of Mining Data Insights in the Life Sciences Industry – 2024 (April 2024)A recent industry-wide survey reveals disconnects and unmet needs pertaining to real-world patient data and analytics that can impact business decision making.
Latest:
Current Status of Biosimilars and Their Impact on PharmacovigilanceAs the market for biosimilars expands, a nuanced approach is needed to balance cost considerations with patient safety and pharmacovigilance efforts.
Latest:
Sustaining Pace With Contingent WorkersPandemic workforce trends continue to create challenges for pharma.
Latest:
Word to the Whyse presents: The Science of Engagement*** Time and Date: Tuesday, November 17 I 11:00 am – 2:30 pm EST *** *** On-demand available after final airing until Nov. 17, 2021***
Latest:
Overcoming HCP Engagement Fatigue with Data-Driven InsightsWith a single source of data united under a single privacy policy, pharma marketers are equipped to plan, engage, measure, and optimize a targeted digital marketing model.
Latest:
Why Program Management is the Key to Success for Life Science CompaniesDelivering value with enterprise program management.
Latest:
Trends to Watch in Patient-first Pharma MarketingAs healthcare increasingly shifts to digital, new pharma marketing and patient engagement trends are emerging at the forefront of care. In this podcast, Phreesia Life Sciences and Pharmaceutical Executive discuss how technology is changing healthcare consumers’ expectations and helping to create more personalized experiences focused on connecting the right patients to the right content, care and resources.
Latest:
Industry Game Changer: RWE Impacts on Drug DevelopmentCOVID may have given real-world evidence the boost it needed to become routine, especially in areas that demand research innovation and advancement.
Latest:
The Harms of ‘Helicopter Research’ in the Life SciencesHow pharma companies can make justice and integrity a priority.
Latest:
Data Intermediaries/Software Can Speed the Usage of Real-World DataSurvey taken by pharma and CRO executives evaluates how effectively various programs convert RWD into usable data.
